Actemra Lawyers Provide Free Case Evaluations
Reports suggest that Actemra may carry the same, if not a higher, risk of certain side effects that have previously been linked to similar drugs. However, the drug maker failed to provide warnings when the rheumatoid arthritis drug was introduced.
As a result of the decision to place their desire for profits before patient safety, Actemra lawsuits may provide financial compensation for individuals who have suffered heart attacks, strokes, heart failure, lung disease, pancreatitis and other side effects from the rheumatoid arthritis drug.
All Actemra cases are handled by our law firm under a contingency fee agreement. This means that there are never any any out-of-pocket costs to hire a lawyer, and there are no attorney fees or expenses unless a recovery is obtained.
To find out whether you or a loved one may be entitled to receive an Actemra settlement, call 1-800-522-0102 or request a free case evaluation by completing our on-line form.
Actemra Infusion and Injection Problems
Actemra (tocilizumab) is a blockbuster rheumatoid arthritis drug introduced by Roche in January 2010. It is delivered as an intravenous Actemra infusion on a monthly basis, or as a subcutaneous Actemra injection on a weekly or bi-weekly basis.
Roche aggressively marketed their new rheumatoid arthritis drug as a “unique” breakthrough treatment, and it has become a blockbuster drug, generating $1.6 billion in sales in 2016, making it one of the top sellers for the global pharmaceutical company.
At the time Actemra was introduced, many popular and widely used rhematoid arthritis drugs were already on the market, including Enbrel, Humira and Remicade.
While these other drugs contained strong warnings about the cardiovascular risks and other health problems, Actemra warnings did not indicate that users may experience a heart attack, stroke, heart failure, lung disease, pancreatitis or other serious side effects. As a result, many doctors and patients were falsely led to believe that Actemra was safer, which does not appear to be the case.
Actemra users may actually face the same, or possibly even a greater, risk of heart problems, lung complications and other injuries.
Report Highlights Failure to Warn About Actemra Risks
In June 2017, the national publication STATNews.com released a detailed review of adverse event reports submitted to the FDA involving Actemra problems. The report raised serious question about the failure to warn about the risk of cardiovascular problems, pancreatitis, lung disease and other injuries that have been experienced by users nationwide.
- More Actemra heart attacks, strokes and heart failure cases were identified than with either Humira or Remicade;
- Interstitial lung disease from Actemra was seen at roughly the same number of cases as Humira, and more than the number experienced by Remicade users;
- Actemra stroke and heart failure rates were about 1.5 times higher than with Enbrel;
- Pancreatitis from Actemra was reported among 132 individuals, including 6 deaths;
STAT identified at least 13,500 reports of issues following an Actemra infusion or injection, which were submitted to the FDA between 2010 and 2016. Among the reports were at least 1,128 Actemra deaths.
Actemra was linked to a higher-than-expected number of serious adverse event reports when compared with the more widely used drugs Humira, Remicade and Enbrel, which each have warnings about risks that users may face.
The independent report concluded that there is “clear evidence” that the users of Actemra face a risk of:
- Heart Attacks
- Heart Failure
- Interstitial Lung Disease
As a result of the failure to warn users about the risk of problems, which Roche knew or should have known about for years, the Actemra injury lawyers at Saiontz & Kirk, P.A. are reviewing cases for individuals nationwide.
Actemra Injury Lawsuit Allegations
According to allegations that will be raised in Actemra lawsuits being pursued against Roche, the drug maker placed their desire for profits before consumer safety by withholding important warnings about the risk of heart attacks, strokes, heart failure, lung disease, pancreatitis and other harmful side effects. Claims are being reviewed for:
- Failure to properly research Actemra side effects before the drug was introduced;
- Failure to follow through on post-marketing Actemra studies to evaluate the heart risks;
- Failure to monitor adverse event reports and disclose serious safety signals;
- Failure to issue an Actemra recall or update warnings after it became apparent that users were experiencing problems at higher-than-expected rates;
- Misrepresenting the safety of Acemtra Infusions and Actemra Injections to Users and the Medical Community;
No Fees or Expenses Unless You Receive an Actemra Settlement
Saiontz & Kirk, P.A. is a nationally known injury law firm that is focused exclusively on representing individuals, we do not represent corporations or insurance companies.
Over the course of more than 40 years, the personal injury lawyers at Saiontz & Kirk, P.A. have collected more than $1 billion in compensation for our clients in cases of medical malpractice, automobile accidents, product liability and other personal injury lawsuits.
All Actemra lawsuits will be handled by our attorneys on a contingency fee basis, which means that there are never any out-of-pocket expenses to hire our law firm and we only receive an attorney fee if we secure compensation for our client.
Protect your family and find out if you or a loved one may be eligible for an Actemra class action lawsuit.